Coptis Chinensis Franch: Substance Basis, Mechanism of Action and Quality Control Standard Revealed Based on the Q-marker Concept and New Strategy of Systemic Pharmacology and Biosynthesis Research
- PMID: 39136504
- DOI: 10.2174/0115680266305274240723120426
Coptis Chinensis Franch: Substance Basis, Mechanism of Action and Quality Control Standard Revealed Based on the Q-marker Concept and New Strategy of Systemic Pharmacology and Biosynthesis Research
Abstract
Coptis chinensis Franch. (Ranunculaceae, Coptis), a traditional Chinese medicine (TCM) with thousands of years of clinical use history, also a natural medicine available in many countries, has wide pharmacological mechanisms and significant bioactivity according to its traditional efficacy combined with modern scientific research. The quality marker (Q-marker) of C. chinensis Franch. is predicted in this paper based on the chemical composition and pharmacological effects of the plant, as well as the current system pharmacology, plant relatedness, biosynthetic pathways and quantitative analysis of multi-components (QAMS). Natural medicine has the advantage of being multi-component, multi-pathway and multi-target. However, there are few reports on safety evaluation. This review predicts the Q-marker of C. chinensis, the safety and efficacy of C. chinensis is provided. Studies from 1975 to 2023 were reviewed from PubMed, Elsevier, ScienceDirect, Web of Science, SpringerLink, and Google Scholar. Alkaloids and organic acids are the two main component categories of Q-Markers. The specific alkaloids identified through predictive results include berberine, coptisine, palmatine, epiberberine, jatrorrhizine, columbamine, and berberrubine. Quinic acid and malic acid, due to their influence on the content of alkaloids and their ability to aid in identifying the active components of C. chinensis, are also considered Q-markers. The research strategy of "exploring chemical components, exploring pharmacological activities, constructing pharmacological mechanism network and locating biosynthetic pathways" was used to accurately screen the quality markers of C. chinensis in this review and summarise the quality evaluation methods and criteria. In addition, we updated the biosynthetic pathway of C. chinensis and refined the specific synthetic pathways of jatrorrhizine (quality markers) and epiberberine (quality markers). Finally, we summarised the quality evaluation methods of C. chinensis, which provide an important reference for resource evaluation and provide a key reference for the discovery of new functional chemical entities for natural medicines.
Keywords: Biosynthesis.; Chemical composition; Coptis chinensis Franch.; Pharmacological effects; Q-marker; System pharmacology.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The interaction of alkaloids in Coptis chinensis Franch -Tetradium ruticarpum (A. Juss.) T.G. Hartley with hOCT1 and hOCT2.J Ethnopharmacol. 2022 Sep 15;295:115395. doi: 10.1016/j.jep.2022.115395. Epub 2022 May 18. J Ethnopharmacol. 2022. PMID: 35597409
-
Isoquinoline Alkaloids from Coptis chinensis Franch: Focus on Coptisine as a Potential Therapeutic Candidate against Gastric Cancer Cells.Int J Mol Sci. 2022 Sep 7;23(18):10330. doi: 10.3390/ijms231810330. Int J Mol Sci. 2022. PMID: 36142236 Free PMC article.
-
The colonic metabolism differences of main alkaloids in normal and colitis mice treated with Coptis chinensis Franch. and Sophora flavescens Ait. herbal pair using liquid chromatography-high resolution mass spectrometry method combined with chemometrics.J Sep Sci. 2023 Jul;46(14):e2300094. doi: 10.1002/jssc.202300094. Epub 2023 Jun 20. J Sep Sci. 2023. PMID: 37339806
-
Coptisine, the Characteristic Constituent from Coptis chinensis, Exhibits Significant Therapeutic Potential in Treating Cancers, Metabolic and Inflammatory Diseases.Am J Chin Med. 2023;51(8):2121-2156. doi: 10.1142/S0192415X2350091X. Epub 2023 Nov 4. Am J Chin Med. 2023. PMID: 37930333 Review.
-
Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies.J Ethnopharmacol. 2021 Mar 25;268:113573. doi: 10.1016/j.jep.2020.113573. Epub 2020 Nov 9. J Ethnopharmacol. 2021. PMID: 33181286 Review.
References
-
- H T.A.; Chinese medicinal plants from the Pen Ts’ao Kang Mu, AD 1596. Nature 1936,138(3490),484 - DOI
-
- Ma J.X.; Shen Nong 's Herbal Classic 2013,43-44
-
- Chen Y.X.; Gao Q.Y.; Zou T.H.; Wang B.M.; Liu S.D.; Sheng J.Q.; Ren J.L.; Zou X.P.; Liu Z.J.; Song Y.Y.; Xiao B.; Sun X.M.; Dou X.T.; Cao H.L.; Yang X.N.; Li N.; Kang Q.; Zhu W.; Xu H.Z.; Chen H.M.; Cao X.C.; Fang J.Y.; Berberine versus placebo for the prevention of recurrence of colorectal adenoma: A multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol 2020,5(3),267-275 - DOI - PubMed
-
- Zhao B.L.; Liu X.Y.; Literatures of rhizoma coptidis. Zhong Yao Cai 2013,36,832-835
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources